EA201201483A1 - METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC SUBSTANCES - Google Patents

METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC SUBSTANCES

Info

Publication number
EA201201483A1
EA201201483A1 EA201201483A EA201201483A EA201201483A1 EA 201201483 A1 EA201201483 A1 EA 201201483A1 EA 201201483 A EA201201483 A EA 201201483A EA 201201483 A EA201201483 A EA 201201483A EA 201201483 A1 EA201201483 A1 EA 201201483A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
subject
motor coordination
fluid
protection against
Prior art date
Application number
EA201201483A
Other languages
Russian (ru)
Inventor
Ричард Л. Уотсон
Энтони Б. Вуд
Грегори Дж. Аршамбо
Original Assignee
Ревалезио Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/771,476 external-priority patent/US20100310609A1/en
Application filed by Ревалезио Корпорейшн filed Critical Ревалезио Корпорейшн
Publication of EA201201483A1 publication Critical patent/EA201201483A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)

Abstract

Предоставлены способы защиты от нейротоксичности или уменьшения нейротоксичности при воздействии нейротоксического вещества, включающие введение электрокинетически измененной жидкости на водной основе, предоставленной здесь, в количестве, достаточном для обеспечения нейропротекции против нейротоксического вещества, предпочтительно обеспечивающей защиту от или снижение потери двигательной координации у субъекта, подвергающегося воздействию нейротоксина. В некоторых аспектах обеспечивается защита или снижение нейротоксин-опосредованного апоптоза нейронов и/или обеспечивается активизация или индуцирование по меньшей мере одной из PI-3 киназ и Akt фосфорилирование в нейронах. Предпочтительно введение жидкости включает введение жидкости до воздействия нейротоксического вещества. Дополнительно обеспечиваются способы сохранения или улучшения двигательной координации у субъекта, имеющего нейродегенеративное состояние или заболевание, включающие введение электрокинетически измененной жидкости на водной основе, как это предусмотрено в настоящем документе, в количестве, достаточном для обеспечения сохранения или улучшения двигательной координации у субъекта.Methods are provided for protecting against neurotoxicity or reducing neurotoxicity when exposed to a neurotoxic substance, including administering an electrokinetically modified water-based fluid provided herein in an amount sufficient to provide neuroprotection against a neurotoxic substance, preferably providing protection against or reducing loss of motor coordination in a subject exposed neurotoxin. In some aspects, protection or reduction of neurotoxin-mediated apoptosis of neurons is provided and / or activation or induction of at least one of PI-3 kinases and Akt phosphorylation in neurons is provided. Preferably, the administration of fluid includes the administration of fluid prior to exposure to a neurotoxic substance. Additionally provided are methods for maintaining or improving motor coordination in a subject having a neurodegenerative condition or disease, including administering an electrokinetically modified water-based fluid, as provided herein, in an amount sufficient to maintain or improve motor coordination in the subject.

EA201201483A 2010-04-30 2011-04-29 METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC SUBSTANCES EA201201483A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/771,476 US20100310609A1 (en) 2007-10-25 2010-04-30 Compositions and methods for treatment of neurodegenerative diseases
US41389910P 2010-11-15 2010-11-15
US201161454409P 2011-03-18 2011-03-18
PCT/US2011/034508 WO2011137317A1 (en) 2010-04-30 2011-04-29 Methods and compositions for protecting against neurotoxic agents

Publications (1)

Publication Number Publication Date
EA201201483A1 true EA201201483A1 (en) 2013-04-30

Family

ID=44861925

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201483A EA201201483A1 (en) 2010-04-30 2011-04-29 METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC SUBSTANCES

Country Status (11)

Country Link
EP (1) EP2563121A4 (en)
JP (1) JP5941908B2 (en)
KR (1) KR20130113314A (en)
CN (1) CN103002734A (en)
AU (1) AU2011245223B2 (en)
BR (1) BR112012027905A2 (en)
CA (1) CA2798127A1 (en)
EA (1) EA201201483A1 (en)
IL (1) IL222757A0 (en)
MX (1) MX2012012634A (en)
WO (1) WO2011137317A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9492404B2 (en) 2010-08-12 2016-11-15 Revalesio Corporation Compositions and methods for treatment of taupathy
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
US20180243247A1 (en) * 2017-02-28 2018-08-30 Bryan J. Katz Drug combinations for cerebrovascular disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1613352A4 (en) * 2003-03-20 2009-04-29 Aquaphotonics Inc Micro-cluster compositions
ITMI20061737A1 (en) * 2006-09-12 2008-03-13 Snam Progetti PROCEDURE FOR THE TRANSPORT OF SULFUR TO LOW RISK AND TO ZERO EMISSION FROM SOLID SULFUR DEPOSITS IN BLOCKS OF CONSIDERABLE DIMENSIONS
US20100310609A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
AU2009241365B2 (en) * 2008-04-28 2015-01-22 Revalesio Corporation Compositions and methods for treating multiple sclerosis

Also Published As

Publication number Publication date
IL222757A0 (en) 2012-12-31
KR20130113314A (en) 2013-10-15
BR112012027905A2 (en) 2015-09-08
JP5941908B2 (en) 2016-06-29
EP2563121A1 (en) 2013-03-06
AU2011245223B2 (en) 2015-11-19
CA2798127A1 (en) 2011-11-03
CN103002734A (en) 2013-03-27
EP2563121A4 (en) 2016-05-11
MX2012012634A (en) 2013-02-26
WO2011137317A1 (en) 2011-11-03
JP2013529195A (en) 2013-07-18
AU2011245223A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
EA201201483A1 (en) METHODS AND COMPOSITIONS FOR PROTECTION AGAINST NEUROTOXIC SUBSTANCES
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112015011830A2 (en) compounds and their methods of use
BR112015008447A2 (en) methods to treat cancer
BR112015026006A2 (en) methods for treating cancer with the use of tor kinase inhibitor combination therapy
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
BR112015020466A8 (en) cdc7 inhibitors, their uses, and pharmaceutical composition
CL2016001629A1 (en) Tricyclic compounds as anticancer agents
BR112015027282A2 (en) fenfluramine for use in the treatment of dravet syndrome
BR112015011456A2 (en) aminopyrimidine compounds as t790m-containing mutant egfr inhibitors
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112015025347A2 (en) 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment
MX368346B (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
BR112015026297A2 (en) combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment
BR112014026058A2 (en) compositions for topical treatment of microbial infections
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2013012661A (en) Bicyclic pyridazine compounds as pim inhibitors.
BR112012024822B8 (en) Compound, use of a compound and pharmaceutical composition
TR201908265T4 (en) Fused 1,4-dihydrodioxine derivatives as inhibitors of heat shock transcription factor 1.
EA201491500A1 (en) FIBROZA TREATMENT METHODS
CL2014003325A1 (en) Compounds derived from difluoro-hexahydro-cyclopentaoxacinyls and difluoro-hexahydro-benzooxacinyls, bace 1 inhibitors; pharmaceutical composition; and its use in the treatment of diseases with elevated levels of beta-amyloid, such as Alzheimer's disease
EA201591698A1 (en) MACRO CYCLIC INHIBITORS OF KINASE LRRK2